Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 6/2008

01-11-2008 | Original Article

R2 resection in pancreatic cancer—does it make sense?

Authors: Jörg Köninger, Moritz N. Wente, Beat P. Müller-Stich, Francesco F. di Mola, Carsten N. Gutt, Ulf Hinz, Michael W. Müller, Helmut Friess, Markus W. Büchler

Published in: Langenbeck's Archives of Surgery | Issue 6/2008

Login to get access

Abstract

Background

The goal of surgical treatment in patients with pancreatic cancer is the complete resection of tumor tissue; however, the intraoperative appraisal of resectability can be difficult. Extensive surgical exploration for definitive clear resectability may lead to R2 resections in single cases.

Patients

We analyzed 38 patients with pancreatic cancer with remaining macroscopic tumor tissue after pancreatic resection, as R0 resection was not possible. Patients were compared to 46 patients with unresectable cancer without distant metastases or peritoneal carcinomatosis, in which a bypass procedure was performed.

Results

Operating time and hospital stay were significantly longer after R2 resection. Intraoperative blood loss was significantly higher; and severe surgical complications and the need for relaparotomy were significantly more frequent after R2 resection. The 30-day mortality rate was higher after R2 resection; this difference was not statistically significant. Median survival was comparable in both groups. Two years after surgery, 22.6% of the patients after R2 resection were still alive compared to 10.9% after bypass surgery.

Conclusion

Tumor debulking is not a treatment option in patients with advanced pancreatic cancer, but the patient is not at a disadvantage compared to bypass procedures if tumor tissue remains and R0 resection cannot be achieved after surgical exploration.
Literature
1.
go back to reference Warshaw AL, Swanson RS (1988) Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 208:541–553PubMedCrossRef Warshaw AL, Swanson RS (1988) Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 208:541–553PubMedCrossRef
3.
go back to reference Mosca F, Giulianotti PC, Balestracci T, Di CG, Pietrabissa A, Sbrana F, Rossi G (1997) Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 122:553–566PubMedCrossRef Mosca F, Giulianotti PC, Balestracci T, Di CG, Pietrabissa A, Sbrana F, Rossi G (1997) Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 122:553–566PubMedCrossRef
5.
go back to reference Yeo CJ (1998) Pancreatic cancer: 1998 update. J Am Coll Surg 187:429–442PubMed Yeo CJ (1998) Pancreatic cancer: 1998 update. J Am Coll Surg 187:429–442PubMed
6.
go back to reference Kuhlmann K, de CS, van HT, Busch O, van GT, Obertop H, Gouma D (2006) Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 139:188–196PubMedCrossRef Kuhlmann K, de CS, van HT, Busch O, van GT, Obertop H, Gouma D (2006) Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 139:188–196PubMedCrossRef
7.
go back to reference Spanknebel K, Conlfson KC (2001) Advances in the surgical management of pancreatic cancer. Cancer J 7:312–323PubMed Spanknebel K, Conlfson KC (2001) Advances in the surgical management of pancreatic cancer. Cancer J 7:312–323PubMed
8.
go back to reference Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Buchler MW, Friess H (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 322:943–949PubMedCrossRef Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Buchler MW, Friess H (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 322:943–949PubMedCrossRef
9.
go back to reference Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL (2000) Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg 66:378–385PubMed Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL (2000) Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg 66:378–385PubMed
10.
go back to reference Johnstone PA, Sindelar WF (1996) Radical reoperation for advanced pancreatic carcinoma. J Surg Oncol 61:7–11PubMedCrossRef Johnstone PA, Sindelar WF (1996) Radical reoperation for advanced pancreatic carcinoma. J Surg Oncol 61:7–11PubMedCrossRef
11.
go back to reference Mann O, Strate T, Schneider C, Yekebas EF, Izbicki JR (2006) Surgery for advanced and metastatic pancreatic cancer—current state and perspectives. Anticancer Res 26:681–686PubMed Mann O, Strate T, Schneider C, Yekebas EF, Izbicki JR (2006) Surgery for advanced and metastatic pancreatic cancer—current state and perspectives. Anticancer Res 26:681–686PubMed
12.
go back to reference Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93:1232–1237PubMedCrossRef Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93:1232–1237PubMedCrossRef
13.
go back to reference Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–594PubMedCrossRef Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–594PubMedCrossRef
14.
go back to reference Muller MW, Friess H, Koninger J, Wente MN, Martin D, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Buchler MW (2008) Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195(2):221–228PubMedCrossRef Muller MW, Friess H, Koninger J, Wente MN, Martin D, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Buchler MW (2008) Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195(2):221–228PubMedCrossRef
15.
go back to reference Schmidt J, Welsch T, Jager D, Muhlradt PF, Buchler MW, Marten A (2007) Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 97:598–604PubMedCrossRef Schmidt J, Welsch T, Jager D, Muhlradt PF, Buchler MW, Marten A (2007) Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 97:598–604PubMedCrossRef
16.
go back to reference Gouma DJ, Nieveen van Dijkum EJ, van Geenen RC, van Gulik TM, Obertop H (1999) Are there indications for palliative resection in pancreatic cancer? World J Surg 23:954–959PubMedCrossRef Gouma DJ, Nieveen van Dijkum EJ, van Geenen RC, van Gulik TM, Obertop H (1999) Are there indications for palliative resection in pancreatic cancer? World J Surg 23:954–959PubMedCrossRef
17.
go back to reference Truty MJ, Urrutia R (2007) Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery 141:1–6PubMedCrossRef Truty MJ, Urrutia R (2007) Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery 141:1–6PubMedCrossRef
18.
go back to reference Lillemoe KD, Cameron JL, Yeo CJ, Sohn TA, Nakeeb A, Sauter PK, Hruban RH, Abrams RA, Pitt HA (1996) Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 223:718–725PubMedCrossRef Lillemoe KD, Cameron JL, Yeo CJ, Sohn TA, Nakeeb A, Sauter PK, Hruban RH, Abrams RA, Pitt HA (1996) Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 223:718–725PubMedCrossRef
19.
go back to reference Reinders ME, Allema JH, van Gulik TM, Karsten TM, de Wit LT, Verbeek PC, Rauws EJ, Gouma DJ (1995) Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple’s resection) for treatment of pancreatic head tumors. World J Surg 19:410–414PubMedCrossRef Reinders ME, Allema JH, van Gulik TM, Karsten TM, de Wit LT, Verbeek PC, Rauws EJ, Gouma DJ (1995) Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple’s resection) for treatment of pancreatic head tumors. World J Surg 19:410–414PubMedCrossRef
20.
go back to reference Huguier M, Baumel H, Manderscheid JC (1996) Cancer of the exocrine pancreas. A plea for resection. Hepatogastroenterology 43:721–729PubMed Huguier M, Baumel H, Manderscheid JC (1996) Cancer of the exocrine pancreas. A plea for resection. Hepatogastroenterology 43:721–729PubMed
21.
go back to reference Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477PubMedCrossRef Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477PubMedCrossRef
Metadata
Title
R2 resection in pancreatic cancer—does it make sense?
Authors
Jörg Köninger
Moritz N. Wente
Beat P. Müller-Stich
Francesco F. di Mola
Carsten N. Gutt
Ulf Hinz
Michael W. Müller
Helmut Friess
Markus W. Büchler
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Langenbeck's Archives of Surgery / Issue 6/2008
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-008-0308-4

Other articles of this Issue 6/2008

Langenbeck's Archives of Surgery 6/2008 Go to the issue